

Feline Coronavirus Serotypes 1 and 2: Seroprevalence and Association with Disease in Switzerland

Maya Kummrow,¹ Marina L. Meli,¹ Michael Haessig,² Enikoe Goenczi,¹
 Amy Poland,³ Niels C. Pedersen,³ Regina Hofmann-Lehmann,¹
 and Hans Lutz^{1*}

Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Switzerland¹; Department of Farm Animals, Vetsuisse Faculty, University of Zurich, Switzerland²; and Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California, Davis, California³

Received 21 March 2005/Returned for modification 13 May 2005/Accepted 26 July 2005

To determine the prevalence of antibodies to feline coronavirus (FCoV) serotypes 1 and 2 in Switzerland and their association with different disease manifestations, a serological study based on immunofluorescence tests was conducted with Swiss field cats using transmissible gastroenteritis virus (TGEV), FCoV type 1 and FCoV type 2 as antigens. A total of 639 serum samples collected in the context of different studies from naturally infected cats were tested. The current study revealed that, with an apparent prevalence of 83%, FCoV serotype 1 is the most prevalent serotype in Switzerland. FCoV type 1 viruses induced higher antibody titers than FCoV type 2, and were more frequently associated with clinical signs and/or feline infectious peritonitis. The antibody development in seven cats experimentally infected with FCoV type 1 revealed that, with progressing duration of infection, antibodies to FCoV type 1 significantly increased over those to FCoV type 2. There was a significant relationship between antibody titers against TGEV, FCoV 1, and FCoV 2 and TGEV antigen detected the highest proportion of seropositive cats. We conclude that a vaccine against FCoV should be based on FCoV type 1-related antigens and that for serodiagnosis of FCoV infection TGEV should be used to attain the highest diagnostic efficiency. When serology is used in addition to clinical signs, hematology, and clinical chemistry results as an aid to diagnose clinical FIP, TGEV shows a diagnostic efficiency equal to that of a FCoV antigen.

Intensive research has been done since the first description of the disease pattern of feline infectious peritonitis (FIP) in 1963 (21), and yet the epidemiology and the pathogenesis of the fatal disease FIP, which is caused by a coronavirus is still not fully understood. It was shown that FIP is the single most important infectious cause of death in young cats, resulting in the loss of 10% of seropositive kittens during the first year of life (6).

As for the pathogenesis, it is generally accepted today that feline coronavirus (FCoV) and FIP-inducing viruses (FIPV) represent virulence variants of the same virus rather than separate virus species (39). Most FCoV mutants do not cause clinical signs, although present at high viral loads; only sporadically mutants are pathogenic and induce FIP (28). In some cases, FCoV infection was found to induce mild enteric symptoms (27, 39). It was postulated earlier that harmless FCoVs were restricted to the intestinal tract and that FIP development would result from the capability of a virus mutant to induce systemic infection (33). In the meantime, it was demonstrated by reverse transcription (RT)-PCR that FCoV generally induces systemic infection (10, 24, 28). Moreover, FCoV and FIPV have remained serologically and genetically indistinguishable.

Antigenetically, coronaviruses are divided into five groups. Together with canine coronavirus (CCoV) and transmissible

gastroenteritis virus (TGEV), FCoV belongs to group I. Cats seem susceptible to all group I coronaviruses (23). Some feline strains are thought to originate from recombinations of FCoV and other group I viruses, such as CCoV (16).

Based on in vitro neutralization tests, FCoVs were further classified into two serotypes which differ in their growth characteristics in cell cultures and antigenetic relationship to TGEV and CCoV; however, both serotypes can cause FIP (7, 32). The serological distinction of FCoV type 1 from type 2 is most likely associated with differences in the S gene sequence as monoclonal antibodies to the S protein readily differentiate the FCoV subtypes (20). Furthermore, FCoV types 1 and 2 have a different cell tropism which can be explained by changes in the S protein binding to different receptors as demonstrated previously (18). Cats recovering from FCoV infection develop especially high titers against the S protein. Many new strains have recently been isolated (1, 4, 15, 17, 25, 35) and phylogenetic examination suggests a spectrum of strains ranging from very feline-like to more canine-like rather than two distinct serotypes (1, 4, 25). Whichever system is applied to classify FCoV, the association between certain FCoV strains and their ability to induce disease could not yet be elucidated.

Knowledge of the serotype circulating in a given population is an important prerequisite for the development of a FCoV vaccine in that the vaccine should be closely related to the field viruses. The present study was initiated to determine the seroprevalence of FCoV types 1 and 2 in Switzerland and find potential associations between the serotypes and certain disease manifestations. In addition, we aimed to characterize the immune response during experimental infection with FCoV 1.

* Corresponding author. Present address: Clinical Laboratory, University of Zurich, Winterthurerstrasse 260, 8057 Zürich, Switzerland. Phone: 41 (0) 44 635 83 12. Fax: 41 446358906. E-mail: hlutz@vetclinics.unizh.ch.

TABLE 1. Origin of samples and grouping for the questions to be answered

Question to be answered	Description				
	Group A: field sera, 1996–1997	Group B: catteries	Group C: histologically confirmed FIP cases	Group D: non-FIP cases ^c , 1991–1995	Group E: experimentally infected cats
Determination of the seroprevalence of FCoV serotypes in Switzerland	296 healthy cats and 204 cats with clinical signs found to be associated with disease and/or FCoV infection ^a	63 samples from 21 catteries ^b	30 sera	28 sera	28 samples from seven cats ^d
Determination of the association between FCoV types and disease/symptoms					
Determination of the immunological relationship between FCoV type 1 and 2 and TGEV					
Determination of the kinetics of the development of antibody titers to FCoV 1 and 2					

^a Cats showing one or more of the following symptoms: fever, cachexia, depression, diarrhea, and gastrointestinal tract and/or abdominal problems.

^b Three pooled sera per cattery.

^c Healthy cats and cats with clinical signs of noninfectious origin (e.g., fracture).

^d Four serum samples from each cat were collected on weeks 3, 12/13, 16/17, and 40/42 after experimental infection with FCoV-Rm (34).

MATERIALS AND METHODS

Cats and serum samples. A total of 667 serum samples collected from naturally and experimentally infected cats during different studies were tested for FCoV antibodies (Table 1).

The kinetic of antibody development was determined in samples collected from cats orally infected with FCoV-Rm, a serotype 1 strain (34). Blood had been taken weekly during the first two months and monthly thereafter up to week 42 after infection (Table 1, group E).

To evaluate the prevalence of FCoV serotype 1 and 2 antibodies, field sera collected in 1996 and 1997 (9) were used. From this collection, we randomly selected samples from 296 cats considered healthy by their owners and veterinarians (Table 1, group A). To determine the predominant FCoV serotype present in catteries, samples were used that had been collected in 21 catteries with different breeds in 2001 and 2002 (14) (Table 1, group B). From each cattery, three randomly selected samples were pooled because of small sample volumes.

To investigate a possible relationship between the presence of antibodies to the two serotypes and clinical signs, samples from the above mentioned 296 healthy cats and 204 clinically ill cats were tested. The latter were presented to veterinarians with one or more clinical signs of disease including fever, cachexia, depression, diarrhea, and gastrointestinal tract and/or abdominal problems. The cats originated from all parts of Switzerland and were of different ages, breeds, husbandry managements, and sexes (Table 1, group A).

To further characterize the relationship between the presence of antibodies to one of the FCoV serotypes and FIP, 30 serum samples were evaluated that had been randomly chosen from a collection of histopathologically confirmed FIP cases accumulated between 1991 and 1995 (36) (Table 1, group C). For a reference group, we randomly selected 28 sera collected from diseased cats without FIP; these serum samples had been stored at the Clinical Laboratory of the Vetsuisse Faculty, University of Zurich, during the same time period (Table 1, group D).

To determine the immunological relationship between FCOVs 1 and 2 and TGEV, serum samples of group A were tested for the respective antibodies.

Immunofluorescence assay (IFA). The FCoV slides and all materials (dilution and rinse buffer, control sera, and mounting fluid) were kindly donated by VMRD, Inc. (Pullman, WA). Two different types of slides were used: FCoV type 1 and type 2, grown on Crandell feline kidney cells (CrFK). The positive control sera had been obtained from ascites of confirmed FIP cases and titrated on both FCoV 1 and FCoV 2 slides. The negative control sera had been collected from clinically healthy cats.

Serial dilutions of 1:100, 1:400, 1:1,600, 1:6,400, 1:25,600, 1:102,400, and 1:409,600 were prepared from all samples. The first screening was done at the dilution of 1:6,400 to avoid false positive results by cross-contamination on the slides. Endpoint titers were then determined by testing the positive samples at the higher dilutions whereas the negative samples were further tested at lower dilutions.

The staining procedure for indirect IFA was performed according to the manufacturer's protocol. Briefly, diluted sera were incubated at 37°C for 30 min, slides were then washed for 10 min before the conjugate (sheep anti-feline immunoglobulin G [IgG] polyclonal antiserum conjugated to fluorescein isothiocyanate) was added for 30 min at again 37°C. After each washing step, the surfaces of the slides were dried with absorbing paper, preventing the wells from drying out. Each well contained infected cells (30%) and uninfected cells (70%), which served as internal negative control.

Serum samples in which antibodies to type 1 were higher than those to type 2 were designated as “antibodies to type 1” and vice versa.

Antibodies to TGEV were tested according to the method of Osterhaus and Horzinek (30).

Quality control of the FCoV and TGEV slides. To test the 10-well slides for absence of potential viral contaminants originating from various feline pathogens handled in our laboratory, cells were removed from the slides by using a sterile scalpel blade and suspended in 200 μ l phosphate-buffered saline (PBS). Total nucleic acids (TNA) were extracted using the MagNA Pure LC total nucleic acid isolation kit (Roche Diagnostics, Rotkreuz, Switzerland) and eluted in 100 μ l elution buffer. The extracts were tested by real-time RT-PCR and PCR for the following pathogens: FCoV (12), feline leukemia virus (FeLV provirus PCR) (37), feline immunodeficiency virus (FIV) (26), feline herpes virus 1 (FHV-1) (40), feline parvovirus (FPV) (28), and feline calicivirus (FCV) (13). FCV was tested with the following modifications: forward primer, 5'-GTT GGA TGA ACT ACC CGC CAA TC-3'; reverse primer, 5'-CAT ATG CGG CTC TGA TGG CTT GAA ACT G-3'; and probe, 5'-6-carboxyfluorescein (FAM)-TCG GTG TTT GAT TTG GCC TG-6-carboxytetramethylrhodamine (TAMRA)-3' (C. Helps, personal communication). As uninfected cells present on the slides,

TABLE 2. Assignment of titers to two categories

Slide type	Low titer	High titer
TGEV	1:25–1:400	1:1,600
FCoV	1:100–1:1,600	1:6,400–1:409,600

serving as the internal negative control, did not show any unspecific fluorescence, the slides were not tested for mycoplasma contamination by PCR.

Molecular characterization of the FCoV 1 and 2 isolates. To further characterize the FCoV strains used for IFA, infected cells were lysed directly on the slides using 500 µl lysis buffer (RLT buffer, RNeasy mini kit; QIAGEN Hombrechtikon, Switzerland) and viral RNA was extracted by means of the RNeasy Mini Kit (QIAGEN). The extracted RNA was checked for FCoV by real-time RT-PCR (12). A region of about 700 base pairs of the S gene of FCoV was amplified using the following primer sets: primer set 1 with forward primer UCD1.3502f (5'-GCA CTT AAT GCT TAT GTG TCT CAA A-3') and reverse primer UCD1.4165r (5'-TGA GCC ATT CAA GGT CAA CA-3'); primer set 2 with forward primer UCD1.3500f (5'-CAG CAC TTA ATG CTT ATG TGT CTC A-3') and reverse primer UCD1.4173r (5'-CAA TCC TGT TGA GCC ATT CAA G-3'); primer set 3 with forward primer FIPV79-1164.3549f (5'-AGC ACT TAA TGC ATT TGT GTC TCA-3') and reverse primer FIPV79-1164.4230r (5'-TTT CAA TTC TAT TGA GCC ATT CAA G-3'); primer set 4 with forward primer KU2.3523f (5'-GCA CTT AAT GCT TAT GTG TCT C-3') and reverse primer KU2.4226r (5'-CAC ACA TAC CAA GGC C-3'); primer set 5 with forward primer KU2.3522f (5'-AGC ACT TAA TGC TTA TGT GTC-3') and reverse primer KU2.4226r (sequence above). Briefly, 2.5 µl RNA was amplified using the SuperScript III one-step RT-PCR system with Platinum Taq kit (Invitrogen Life Technologies, Basel, Switzerland), 0.2 µM concentrations of each primer, in a total volume of 25 µl. PCR cycling conditions were as follows: 30 min at 50°C (RT step), 2 min at 94°C, 40 cycles of 15 s at 94°C (denaturation), 30 s at 55°C (annealing), and 1 min at 68°C (elongation), followed by 5 min at 68°C.

PCR products from conventional PCR were analyzed on 2% agarose gels; amplicons were purified using the MinElute gel extraction kit (QIAGEN) and sequenced from both sides. Cycle sequencing was performed with approximately 20 ng of DNA and 3.3 pmol product-specific primers using the BigDye Terminator Cycle Sequencing Ready Reaction Kit v1.1 (Applied Biosystems, Rotkreuz, Switzerland). Cycling conditions were as follows: 1 min at 96°C, then 25 cycles at 96°C for 30 s and 50°C for 15 s, followed by 60°C for 4 min. Products were purified using the DyeEx Spin column (QIAGEN), and analyzed on the ABI Prism 310 genetic analyzer (Applied Biosystems). The sequences obtained from the five primer sets were aligned to one consensus sequence by SeqScape (version 1.1; Applied Biosystems) and then compared to reference sequences of the FCoV S gene deposited in the GenBank: KU2 (D32044) and UCD1 (AB088222) for typical type 1 strains and FIPV79-1183 (X80799) and FIPV79-1164 (X06177) for type 2 strains.

Statistical evaluation. Statistical analyses were performed using StatView 5.1 (SAS Institute Inc., Cary, NC) and Microsoft Excel. To characterize frequencies of antibodies to serotypes with respect to significant differences in the different groups of cats, the χ^2 -test was applied. To evaluate the height of titers in the different groups of cats, titers were divided into two groups (Table 2). The association between the nature of symptoms and the serotypes was evaluated by means of multivariate logistic regression model. To determine the immunological relationship between FCoVs 1 and 2 and TGEV, the coefficient of correlation and the regression coefficient using the least square method were applied. To characterize the kinetic of antibody development for significant differences, antibody titers were analyzed by analysis of variance (ANOVA), factorial and repeated measures method, and Fisher's protected least-significant difference post hoc test for factorial ANOVA. For the comparison of mean titers, the Kruskal-Wallis and the Mann-Whitney U test were used. Comparison of groups was performed by using the χ^2 test and the post hoc cell contribution as well as multivariate logistic regression model. *P* values of <0.05 were considered statistically significant. For the presentations of frequency distributions in Fig. 3 and 4, box plots were used with the upper and lower levels of the boxes representing the 75th and 25th quartiles, the line in between representing the median and the whiskers the 2.5th and 97.5th quartile. Outliers are shown as individual dots.

TABLE 3. Homology of FCoV antigens on IFA slides with FCoV reference strains

FCoV slide	% Homology			
	FCoV type 1 strains		FCoV type 2 strains	
	UCD 1	KU2	79–1183	79–1164
FIP 1	91.9	91.8	62.6	61.8
FIP 2	61.8	62.3	94.4	95.3

RESULTS

Quality control of the FCoV and TGEV slides. The RT-PCR and PCR testing for potentially contaminating pathogens yielded negative results with the exception of FCoV RT-PCR, which was highly positive (TaqMan cycle threshold values of 18 and 21 for FCoV type 1 and FCoV type 2, respectively, suggesting presence of comparable amounts of viral RNA).

Molecular characterization of the FCoV 1 and 2 isolates. Partial sequencing of the S gene of FCoV isolated from FIP1 and FIP2 slides (GenBank accession numbers DQ122858 and DQ122859, respectively) revealed a high homology with prototypes of FCoV type 1 and 2 strains, respectively (Table 3).

Development of antibody titers to FCoV type 1 and 2 during experimental infection. The course of infection was followed in seven cats, experimentally infected with a FCoV type 1 strain, over a period of 40 to 42 weeks (Fig. 1). Antibody titers to type 1 but not type 2 increase significantly after week 17 of the experiment. Of note, the cats survived the experiment and showed no clinical signs; the rise of FCoV 1 antibody titers did not reflect FIP development.

Prevalence of FCoV serotypes in Switzerland. Among 296 clinically healthy cats (group A), 50% were FCoV seropositive. In 35.1% of the tested animals, titers to FCoV 1 were higher than those to FCoV 2, while in 4.4% of the cats it was vice versa, and 10.5% showed identical titers for both FCoV types (Fig. 2).

There was no statistically significant association between the husbandry conditions (multicat vs. single cat household) and

FCoV antibody titer (log 10)




FIG. 1. Course of mean titers of antibodies to both FCoV 1 and 2 serotypes in cats experimentally infected with FCoV serotype 1. A statistically relevant specification of the immune system to the FCoV serotype of infection can be seen 40/42 weeks after infection (ANOVA with repeated measures, *P* = 0.038).




FIG. 2. Prevalence of FCoV serotypes in different Swiss cat groups. Numbers on bars indicate the percentage of samples within the according group (A through D) referring to the four categories on the x axis. Categories are defined as follows: neg, antibody titers to both FCoV serotypes below detectable level; FCoV 1, antibody titers to FCoV 1 greater than antibody titers to FCoV 2; FCoV 2, antibody titers to FCoV 2 greater than antibody titers to FCoV 1; FCoV 1 = FCoV 2, antibody titers to FCoV equal to antibody titers to FCoV 2.

the prevalence of FCoV serotypes (χ^2 test, $P = 0.07$). High titers ($\geq 1:1,600$) to FCoV were more frequently found in cats from multicat than in single cat households although the difference was not significant (χ^2 test, $P = 0.06$). Antibodies to FCoV type 2 had a tendency to be less frequent in multicat households (χ^2 test, $P = 0.07$).

In 15 (71%) of the 21 Swiss catteries (group B), antibodies to type 1 were predominant, while in 6 (29%) catteries, antibodies to type 1 and 2 were equal in height. Antibodies to type 2 were predominant in none of the catteries (Fig. 2).

In all cats analyzed, antibody titers against FCoV type 1 were significantly higher than those against FCoV type 2 (Fig. 3).

Association between the FCoV serotype and the clinical manifestation. Among the 500 field sera from 1996 and 1997 (group A), seropositivity to FCoV (type 1 or type 2) was significantly higher in cats with clinical signs than in healthy cats (χ^2 test, $P = 0.01$). In this association, antibodies to type 1 were of predominant importance for clinical signs. However, no statistically significant association was found between the presence of antibodies to type 1 and any of the six categories of clinical signs previously found to be associated with possible

FCoV infection (multivariate logistic regression model, $P > 0.05$).

All of the 30 samples from histopathologically confirmed FIP cases (group C) were seropositive. In 25 cats (83%), type 1 titers were higher than those to type 2; the remaining 5 animals (17%) had identical titers to both serotypes. In none of the cats were the titers to type 2 higher than those to type 1 (Fig. 2). In the reference group of non-FIP cases (group D), 43% were seronegative, 50% tested higher for type 1 than for type 2, 7% showed identical titers to both types, and in no cat were the titers to type 2 higher than those to type 1 (Fig. 2). The distribution of titers to the FCoV 1 and 2 serotypes did not differ significantly between groups A and D (χ^2 test, $P > 0.2$). Compared to non-FIP cases, the FIP cases had a significantly higher seroprevalence of FCoV antibodies than any other group (χ^2 test, $P < 0.001$). In addition, the prevalence of




FIG. 3. Box-plot distribution of titers to FCoV types 1 and 2. In cats with antibodies to FCoV type 1 ($1 > 2$), the titers were significantly higher than in cats with antibodies to FCoV type 2 ($2 > 1$) and equal titers ($1 = 2$; Kruskal-Wallis, $P < 0.0001$).




FIG. 4. Box plot distribution of FCoV (serotype 1 and 2) and TGEV antibody titers of FIP (group C) and non-FIP cases (group D). FIP cases show significantly higher FCoV/TGEV antibody titers than non-FIP cases (Mann-Whitney U test, $P < 0.0001$ for both FCoV and TGEV). The ratio of median titers of FIP and non-FIP cases was identical for both FCoV and TGEV antigens.




FIG. 5. Immunological relationship between FCoV types 1 and 2 and TGEV displayed as intersections. Of a total of 500 serum samples, 140 tested negative for coronavirus while the remaining 360 samples within the circles depicted with broken lines tested positive on at least one of the three types of immunofluorescence slides. A total of 210 samples tested positive on all three types of test slides, while 88 samples were detected positive on TGEV slides and 3 on FCoV 1 only.

antibodies to FCoV 1 was significantly higher in the FIP group than their reference group D (χ^2 test, $P < 0.0001$).

No association could be detected between the height of titer and the type of clinical signs (χ^2 test, $P > 0.2$). However, mean titers to FCoV type 1 in confirmed FIP cases were statistically higher than titers to FCoV type 1 and 2 in the control group without FIP (χ^2 test, $P < 0.0001$) (Fig. 4).

Immunological relationship between FCoV type 1 and 2 and TGEV and diagnostic efficiency. The positive correlation of titers between FCoVs 1 and 2 ($r = 0.76$, $P < 0.0001$), FCoV type 1 and TGEV ($r = 0.46$, $P < 0.0001$), and FCoV type 2 and TGEV ($r = 0.44$, $P < 0.0001$) confirmed the close immunological relationship of the three antigens tested.

The number of positive IFA results with FCoV 1 was similar to that obtained with FCoV 2 but lower than using TGEV (Fig. 5). There were 88 samples that tested positive for TGEV but negative for FCoV; of these samples, 72% had a titer of 25, 27% had a titer of 100, and 1% had a titer of 400. When serology in addition to the evaluation of clinical parameters, hematology, and clinical chemistry results was used as an aid to diagnose clinical FIP, TGEV antigen yielded a diagnostic efficiency identical to that of both FCoV serotypes (Fig. 4).

DISCUSSION

We have analyzed 667 serum samples from Swiss field cats and experimentally infected cats for FCoV antibodies by using FCoV type 1 and type 2 and TGEV slides. We found a prevalence of FCoV 1 antibodies (68%) greater than that of FCoV 2 antibodies (9%) while 23% of the cats had equally high titers to types 1 and 2.

Using molecular assays, we demonstrated that the antigen preparations were free of contaminating agents including FeLV, FIV, FHV-1, FPV, and FCV. Based on sequencing analyses of part of the FCoV S gene, a clear assignment of the two viruses to prototype FCoV 1 and 2 was possible confirming the validity of the slides for serodiagnosis of antibodies to FCoV 1 and 2.

Differentiation of antibodies to type 1 over type 2 occurs late in experimental FCoV 1 infection. When the antibody development to FCoV 1 and 2 was followed in experimentally

FCoV-1-infected cats, it became clear that only after an observation period of more than 17 weeks antibodies to FCoV 1 showed a significant increase over those to FCoV 2. It suggests that during the early phase of the infection cross-reacting epitopes of both types are responsible for comparable titers. From this experiment we conclude that the B lymphocytes involved undergo constant stimulation resulting in increasing concentrations of antibodies and affinity maturation (29) leading to ever higher antibody specificity to the infecting agent, i.e., to FCoV 1 over FCoV 2. Hence, a serological differentiation between antibodies to FCoVs 1 and 2 may not be possible in the early phase of infection but only after the infection has resulted in an increase of antibody concentration and specificity.

Prevalence increase of FCoV serotypes in Switzerland. The prevalence of antibodies to FCoV in the healthy field cats was found to vary between 14.6% in Japan (19) to >70% in Austria (35). We now report a FCoV seroprevalence of 50% in healthy Swiss cats; this is more than twofold higher than what we had found in a study in 1987 (27). Explanations for this increase include differences in sample selection and/or serologic tests. While in the earlier study, TGEV slides were used, we now compared TGEV with FCoV type 1 and 2 slides; all three antigens gave comparable results. Therefore, the prevalence increase cannot be attributed to the antigens used. In both studies, the criteria for sample submission were identical, i.e., the veterinarians submitted samples from which they had a personal interest in obtaining the results. The two studies were similar with respect to the origin of the samples (single versus multicat households). Thus, the observed increase may indeed reflect an increase in seroprevalence between 1987 and 1997.

We found predominantly FCoV type 1 antibodies (68%); this is in agreement with other serological surveys although the distribution varies to some degree (1, 19, 32, 35, 38). In parallel to our experimental study, we hypothesize that serum samples with antibody titers to FCoV type 1 that are greater than those to type 2 originate from cats that had been FCoV type 1 infected for more than 17 weeks. Field cats with titers to FCoV type 1 equal to type 2 (23%) may represent cats infected with both serotypes or by either virus for a short period. Cats with titers to FCoV type 2 that were greater than those to type 1 (9%) were considered to be infected by a type 2 virus assuming that the antibody development after infection with a type 2 FCoV mirrors that of a type 1 infection with specific antibodies to FCoV type 2 increasing over those to type 1 with time. Overall, it becomes clear that the true prevalence of type 1 and 2 infection cannot be determined precisely as the status of the 23% of cats displaying identical titers to type 1 and 2 remains unresolved.

In an earlier report (15), it was stated that cats infected with FCoV are not readily superinfected by antigenically related coronaviruses. However, this observation could not be confirmed by PCR studies conducted by others (3, 11, 19). Among the cats with identical titers to both serotypes the majority (59%) had high titers ($\geq 1,600$). This may reflect coinfection by both serotypes. Alternatively, it could be explained by an infection caused by a strain not identical but immunologically equally related to both strains used in the current study. Additionally, equal titers to both FCoV types could also be ex-

plained by antibodies against other structural proteins present in both viruses, such as the M and N proteins.

Based on the assumption that the virus serotypes within a cattery cluster around one strain (2, 15, 25), we tested pooled serum samples of randomly selected Swiss catteries for their predominant serotype. In none of the catteries antibody titers to type 2 were predominant. Along with the low seroprevalence of type 2 in individual cats, these data support the hypothesis that the type typically known as type 2 does not occur very frequently in the field. In spite of this, type 2 viruses are most frequently used in laboratories. This may not reflect their importance in the field but rather their ease of cultivation *in vitro*.

It has been reported that the type 2 FCoV originates from recombination between coronaviruses of cats and dogs (16). An association between presence of dogs and serotype 2 FCoV could not be confirmed due to the retrospective nature of the study in which no information on the presence of dogs had been recorded. It could be imagined that some of the type 2 viruses have suboptimal replication activities *in vivo* which may explain lower viral loads resulting from infection with these viruses. This may explain the significantly lower antibody titers in cats infected with FCoV type 2 compared with those infected with type 1.

The understanding of the mechanisms of the development of FIP from a FCoV infection is of urgent practical importance to cat owners in terms of husbandry measures. An association between multicat environment and height of antibody titers and the prevalence of FCoV infection was found in our study confirming other reports (8, 27).

Association between the FCoV serotype and the clinical manifestation. Antibodies against type 1 are overrepresented in diseased cats. Additionally, there is a tendency for type 2 to be less often present, however not at a statistically significant level. Similarly, in Japan, 80.4% and 10.1% of chronically diseased cats tested positive for FCoV type 1 and type 2, respectively (19). Thus, FCoV type 1 viruses may be more likely to replicate to high viral load, induce higher antibody titers, and thereby may become more frequently associated with chronic disease and/or FIP. Again, this can be explained by the better adaptation of type 1 to cats. In our study, 100% of confirmed FIP cases were seropositive to FCoV. This high seroprevalence in FIP cases was significantly higher than that of the healthy cat population and corresponds well with 87% and 96% found in other studies (5, 31). All of our FIP samples tested positive for type 1 or both types similarly. We could not find a single FIP case testing higher for type 2. Thus, the above mentioned hypothesis of FCoV type 1 being of higher pathogenicity than type 2 appears to be true also for FIP development.

Although confirmed FIP cases showed significantly increased antibody titers to FCoV, no significant association could be found with height of titers and the category of clinical signs.

Immunological relationship between FCoV type 1 and 2 and TGEV and implication for serotesting. The statistically significant correlation of antibody titers to FCoV 1/FCoV 2, FCoV 1/TGEV, and FCoV 2/TGEV suggest close immunological relationship. From Fig. 5, it becomes evident that TGEV as the IFA substrate allowed the detection of 88 cats to be seropositive which would not have been detected using FCoV 1 or

FCoV 2 antigens. The low titers of these samples (73% with titers of 25 and 27% with titers of 100) suggest that TGEV may be a better substrate, i.e., produces higher concentrations of viral antigens in its pig cell line than FCoV 1 and 2 grown in cat cells. Alternatively, the antibodies present in these 88 samples could have been induced by a third type of FCoV currently not known which is more closely related to TGEV than FCoV. For the diagnosis of clinical FIP (36), TGEV is equally suited as FCoV. Therefore, for FIP diagnosis, either FCoV or TGEV can be used. It is emphasized, however, that coronavirus titers alone must not be used as single parameter for FIP diagnosis (22). However, if seropositivity is to be detected, TGEV in pig cells appears to be better suited.

In conclusion, it was demonstrated that FCoV type 1 is the most prevalent FCoV serotype in Switzerland and with this the distribution is quite similar to that in other parts of the world. This information may be important for the development of future FCoV vaccines. Differentiation of the antibody response to FCoV 1 and 2 does not seem to be very helpful to obtain information of the disease process in a given cat. However, the antigens used in this study proved to be highly valuable for the differentiation of antibodies with specificity for FCoV 1 and 2.

ACKNOWLEDGMENTS

We thank VMRD, in particular, Scott Adams and John Black, for donating the FIP 1 and 2 IFA slides. We are grateful to R. de Groot and B. J. Haijema, who kindly provided type 2 FCoV ascites for quality testing. We also thank E. Rogg and E. Rhiner for excellent laboratory assistance.

This study was supported by the Swiss Union Bank on behalf of a customer. The study was performed using the logistics of the Centre for Clinical Studies at the Vetsuisse Faculty of the University of Zurich. R. Hofmann-Lehmann is the recipient of a professorship by the Swiss National Science Foundation (PP00B-102866).

REFERENCES

1. Addie, D., I. A. Schaap, L. Nicolson, and O. Jarrett. 2003. Persistence and transmission of natural type I feline coronavirus infection. *J. Gen. Virol.* **84**:2735–2744.
2. Addie, D. D. 2000. Clustering of feline coronaviruses in multicat households. *Vet. J.* **159**:8–9.
3. Addie, D. D., and J. O. Jarrett. 1992. Feline coronavirus antibodies in cats. *Vet. Rec.* **131**:202–203.
4. Battilani, M., T. Coradin, A. Scagliarini, S. Ciulli, F. Ostanello, S. Proserpi, and L. Morganti. 2003. Quasispecies composition and phylogenetic analysis of feline coronaviruses (FCoVs) in naturally infected cats. *FEMS Immunol. Med. Microbiol.* **39**:141–147.
5. Benetka, V., A. Kubber-Heiss, J. Kolodziejek, N. Nowotny, M. Hofmann-Parisot, and K. Mostl. 2004. Prevalence of feline coronavirus types I and II in cats with histopathologically verified feline infectious peritonitis. *Vet. Microbiol.* **99**:31–42.
6. Fehr, D., S. Bolla, A. Herrewegh, M. Horzinek, and H. Lutz. 1996. Detection of feline coronavirus using RT-PCR: basis for the study of the pathogenesis of feline infectious peritonitis (FIP). *Schweiz Arch. Tierheilkd.* **138**:74–79. (In German.)
7. Fiscus, S. A., and Y. A. Teramoto. 1987. Antigenic comparison of feline coronavirus isolates: evidence for markedly different peplomer glycoproteins. *J. Virol.* **61**:2607–2613.
8. Foley, J. E., A. Poland, J. Carlson, and N. C. Pedersen. 1997. Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. *J. Am. Vet. Med. Assoc.* **210**:1313–1318.
9. Gruber, S. 2000. FeLV-Provirusbürde und -Prävalenz bei natürlichen und experimentell mit FeLV infizierten Katzen, Inaugural dissertation. University of Zurich, Zurich, Switzerland.
10. Gunn-Moore, D., T. Gruffydd-Jones, and D. Harbour. 1998. Detection of feline coronaviruses by culture and reverse transcriptase-polymerase chain reaction of blood samples from healthy cats and cats with clinical feline infectious peritonitis. *Vet. Microbiol.* **62**:193–205.
11. Gunn-Moore, D. A., F. J. Gunn-Moore, T. J. Gruffydd-Jones, and D. A. Harbour. 1999. Detection of FCoV quasispecies using denaturing gradient gel electrophoresis. *Vet. Microbiol.* **69**:127–130.

12. Gut, M., C. Leutenegger, J. Huder, N. Pedersen, and H. Lutz. 1999. One-tube fluorogenic reverse transcription-polymerase chain reaction for the quantitation of feline coronaviruses. *J. Virol. Methods* **77**:37–46.
13. Helps, C., P. Lait, S. Tasker, and D. Harbour. 2002. Melting curve analysis of feline calicivirus isolates detected by real-time reverse transcription PCR. *J. Virol. Methods* **106**:241–244.
14. Helps, C. R., P. Lait, A. Damhuis, U. Björnehammar, D. Boltad, C. Brovida, L. Chabanne, H. Egberink, G. Ferrand, A. Fontbonne, M. Grazia Pennisi, T. Gruffydd-Jones, D. Gunn-Moore, K. Hartmann, H. Lutz, E. Malandain, K. Möstl, C. Stengel, D. A. Harbour, and E. A. M. Graat. 2005. Factors associated with upper respiratory tract disease caused by feline herpesvirus, feline calicivirus, *Chlamydomydia felis* and *Bordetella bronchiseptica* in cats: experience from 218 European catteries. *Vet. Rec.* **156**:669–673.
15. Herrewegh, A., M. Mahler, H. Hedrich, B. Haagmans, H. Egberink, M. Horzinek, P. Rottier, and R. de Groot. 1997. Persistence and evolution of feline coronavirus in a closed cat-breeding colony. *Virology* **234**:349–363.
16. Herrewegh, A., I. Smeenk, M. Horzinek, P. Rottier, and R. de Groot. 1998. Feline coronavirus type II strains 79–1683 and 79–1146 originate from a double recombination between feline coronavirus type I and canine coronavirus. *J. Virol.* **72**:4508–4514.
17. Herrewegh, A. A., H. Vennema, M. C. Horzinek, P. J. Rottier, and R. J. de Groot. 1995. The molecular genetics of feline coronaviruses: comparative sequence analysis of the ORF7a/7b transcription unit of different biotypes. *Virology* **212**:622–631.
18. Hohdatsu, T., Y. Izumiya, Y. Yokoyama, K. Kida, and H. Koyama. 1998. Differences in virus receptor for type I and type II feline infectious peritonitis virus. *Arch. Virol.* **143**:839–850.
19. Hohdatsu, T., S. Okada, Y. Ishizuka, H. Yamada, and H. Koyama. 1992. The prevalence of types I and II feline coronavirus infections in cats. *J. Vet. Med. Sci.* **54**:557–562.
20. Hohdatsu, T., S. Okada, and H. Koyama. 1991. Characterization of monoclonal antibodies against feline infectious peritonitis virus type II and antigenic relationship between feline, porcine, and canine coronaviruses. *Arch. Virol.* **117**:85–95.
21. Holzworth, J. 1963. Some important disorders of cats. *Cornell Vet.* **53**:157–160.
22. Horzinek, M. C., and H. Lutz. 2000. An update on feline infectious peritonitis. *Vet. Sci. Tomorrow* **0**:1–9.
23. Horzinek, M. C., H. Lutz, and N. C. Pedersen. 1982. Antigenic relationships among homologous structural polypeptides of porcine, feline, and canine coronaviruses. *Infect. Immun.* **37**:1148–1155.
24. Kipar, A., S. Bellmann, D. A. Gunn-Moore, W. Leukert, K. Kohler, S. Menger, and M. Reinacher. 1999. Histopathological alterations of lymphatic tissues in cats without feline infectious peritonitis after long-term exposure to FIP virus. *Vet. Microbiol.* **69**:131–137.
25. Kiss, I., S. Kecskemeti, J. Tanyi, B. Klingeborn, and S. Belak. 2000. Prevalence and genetic pattern of feline coronaviruses in urban cat populations. *Vet. J.* **159**:64–70.
26. Leutenegger, C. M., D. Klein, R. Hofmann-Lehmann, C. Mislin, U. Hummel, J. Boni, F. Boretti, W. H. Guenzburg, and H. Lutz. 1999. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system. *J. Virol. Methods* **78**:105–116.
27. Lutz, H., R. Lehmann, G. Winkler, B. Kottwitz, A. Dittmer, C. Wolfensberger, and P. Arnold. 1990. Feline immunodeficiency virus in Switzerland: clinical aspects and epidemiology in comparison with feline leukemia virus and coronaviruses. *Schweiz Arch. Tierheilkd.* **132**:217–225. (In German.)
28. Meli, M., A. Kipar, C. Muller, K. Jenal, E. Gonczi, N. Borel, D. Gunn-Moore, S. Chalmers, F. Lin, M. Reinacher, and H. Lutz. 2004. High viral loads despite absence of clinical and pathological findings in cats experimentally infected with feline coronavirus (FCoV) type I and in naturally FCoV-infected cats. *J. Feline Med. Surg.* **6**:69–81.
29. Neuberger, M. S., M. R. Ehrenstein, C. Rada, J. Sale, F. D. Batista, G. Williams, and C. Milstein. 2000. Memory in the B-cell compartment: antibody affinity maturation. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **355**:357–360.
30. Osterhaus, A. D., M. C. Horzinek, and D. J. Reynolds. 1977. Seroepidemiology of feline infectious peritonitis virus infections using transmissible gastroenteritis virus as antigen. *Zentbl. Veterinärmed. B* **24**:835–841. (In German.)
31. Pedersen, N. C. 1976. Serologic studies of naturally occurring feline infectious peritonitis. *Am. J. Vet. Res.* **37**:1449–1453.
32. Pedersen, N. C., J. W. Black, J. F. Boyle, J. F. Evermann, A. J. McKeirnan, and R. L. Ott. 1984. Pathogenic differences between various feline coronavirus isolates. *Adv. Exp. Med. Biol.* **173**:365–380.
33. Pedersen, N. C., J. F. Boyle, and K. Floyd. 1981. Infection studies in kittens, using feline infectious peritonitis virus propagated in cell culture. *Am. J. Vet. Res.* **42**:363–367.
34. Poland, A. M., H. Vennema, J. E. Foley, and N. C. Pedersen. 1996. Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. *J. Clin. Microbiol.* **34**:3180–3184.
35. Posch, A., U. Posch, A. Kübber-Heiss, I. Stur, M. Seiser, and K. Möstl. 2001. Feline Coronaviren: Differenzierung der Typen I und II mittels RT-PCR und deren Vorkommen in Österreichischen Katzepopulationen. *Wien. Tierärztl. Mschr.* **88**:1–9.
36. Rohrer, C., P. F. Suter, and H. Lutz. 1993. Die Diagnostik der Felinen Infektiösen Peritonitis (FIP): Retrospektive und Prospektive Untersuchungen. *Kleintierpraxis* **6**:379–381.
37. Tandon, R., V. Cattori, M. A. Gomes-Keller, M. L. Meli, M. C. Golder, H. Lutz, and R. Hofmann-Lehmann. 26 July 2005. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. *J. Virol. Methods* doi:10.1016/j.jviromet.2005.06.017.
38. Vennema, H. 1999. Genetic drift and genetic shift during feline coronavirus evolution. *Vet. Microbiol.* **69**:139–141.
39. Vennema, H., A. Poland, J. Foley, and N. Pedersen. 1998. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. *Virology* **243**:150–157.
40. Vögtlin, A., C. Fraefel, S. Albini, C. M. Leutenegger, E. Schraner, B. Spiess, H. Lutz, and M. Ackermann. 2002. Quantification of feline herpesvirus 1 DNA in ocular fluid samples of clinically diseased cats by real-time TaqMan PCR. *J. Clin. Microbiol.* **40**:519–523.